RARE ULTRAGENYX PHARMACEUTICAL INC Product Launches 8-K Filing 2024 - New Data from Phase 1/2 Study of GTX-102 for Angelman Syndrome Treatment Ultragenyx Pharmaceutical Inc. announced new data from a Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome, showing rapid and clinically meaningful improvement in patients.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC